Wednesday 28 October 2009
FOR IMMEDIATE RELEASE
Melbourne-based biotech Acrux was today recognised for its excellence within the Australian biotechnology sector, with
CEO Richard Treagus accepting the AusBiotech –Roche 2009 Excellence Award for outstanding contribution to the
biotechnology industry by a company at the AusBiotech 2009 conference this morning.
Acrux recently announced excellent trial results for their product Axiron, marking a resounding success for the company,
its shareholders and more broadly for the Australian biotechnology sector.
Acrux’s announcement of successful Phase III results for Axiron makes it one of a small number of Australian companies
to have achieved this milestone. Axiron is in development as the first medicine of its kind to treat men with
testosterone deficiency, and is applied to the underarm in a similar way to a deodorant.
“It is wonderful to see an Australian company and AusBiotech member leading in this way and proves that an Australian
company has the capacity and capability to take a product to Phase III on its own,” said Dr Anna Lavelle, CEO of
AusBiotech.
AusBiotech is the national body for the biotechnology and life sciences industry, hosting AusBiotech 2009 – the premier
Australasian biotechnology conference from 27 – 30 October in Melbourne.
ENDS